Clinical trial
A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout
NCT07889284 is registered in ClinicalTrials.gov with ScandiBio Therapeutics AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout
- Lead sponsor
- ScandiBio Therapeutics AB
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- February 28, 2027
- Enrollment
- 336 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
gout disease
Arms
As registered; 2 arms.
-
Treatment Arm
-
Placebo Arm
Primary endpoints
Registered primary outcome measures; 1 primary.
-
To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo.
Absolute change in serum uric acid levels from baseline to end-of-treatment (4 weeks).
Lead sponsor's other trials
ScandiBio Therapeutics AB, most recent start first.
Similar trials
Same condition (Hyperuricemia) and phase, most recent start first.
+8 more trials See the condition page